MedPath

Correlation analysis of HIF-1a and CA15-3 in response to neoadjuvant chemotherapy in locally advanced breast cancer

Not Applicable
Conditions
Cancer
ocally advanced breast cancer
Malignant neoplasm of breast
Registration Number
ISRCTN63220723
Lead Sponsor
RSUP Prof. dr. R. D. Kandou Manado
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Ongoing
Sex
Female
Target Recruitment
10
Inclusion Criteria

1. LABC with a histopathologically confirmed diagnosis of invasive ductal carcinoma
2. NAC regimen of cisplatin (80 mg/BSA) and gemcitabine (1,000 mg/BSA) in two cycles
3. Karnofsky Performance Status Scale >70%

Exclusion Criteria

1. Receiving chemotherapy with radiotherapy
2. Bilateral BC
3. Abnormal hematological parameters
4. Changes in chemotherapy regimen
5. Patients with an inherited metabolic disorder or comorbidities resulting in delayed chemotherapy
6. Acute or chronic obstructive pulmonary disease with SpO2 under 96%

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
HIF-1a and CA15-3 serum levels measured using ELISA at baseline and after receiving two cycles of NAC (Neoadjuvant chemotherapy) in a period of 5 weeks
Secondary Outcome Measures
NameTimeMethod
esion measurement recorded in matrix notation using a clinical caliper and evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at baseline and after receiving two cycles of NAC (Neoadjuvant chemotherapy) in a period of 5 weeks
© Copyright 2025. All Rights Reserved by MedPath